Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Mar 16;47(2):298-308.
doi: 10.1093/schbul/sbaa153.

Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis

Damien Etchecopar-Etchart  1 , Theo Korchia  1 , Anderson Loundou  1 , Pierre-Michel Llorca  2 , Pascal Auquier  1 , Christophe Lançon  1 , Laurent Boyer  1 , Guillaume Fond  1
Affiliations
Meta-Analysis

Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis

Damien Etchecopar-Etchart et al. Schizophr Bull. .

Abstract

Comorbid major depressive disorder (MDD) in schizophrenia (SZ; SZ-MDD) has been identified as a major prognostic factor. However, the prevalence and associated factors of SZ-MDD have never been explored in a meta-analysis. All studies assessing the prevalence of SZ-MDD in stabilized outpatients with a standardized scale or with structured interviews were included. The Medline, Web of Science, PsycINFO, and Google Scholar databases were searched. Using random effects models, we calculated the pooled estimate of the prevalence of SZ-MDD. We used meta-regression and subgroup analyses to evaluate the potential moderators of the prevalence estimates, and we used the leave-one-out method for sensitivity analyses. Of the 5633 potentially eligible studies identified, 18 studies (n = 6140 SZ stabilized outpatients) were retrieved in the systematic review and included in the meta-analysis. The pooled estimate of the prevalence of SZ-MDD was 32.6% (95% CI: 27.9-37.6); there was high heterogeneity (I2 = 92.6%), and Egger's test did not reveal publication bias (P = .122). The following factors were found to be sources of heterogeneity: publication in or after 2015, the inclusion of patients from larger studies, the assessment tools, the inclusion of patients with substance use disorder or somatic chronic diseases, age, education level, the lifetime number of hospitalizations, and antidepressant use. Two-thirds of the extracted variables could not be explored due to an insufficient amount of published data. The prevalence of MDD is high among SZ individuals. Healthcare providers and public health officials should have an increased awareness of the burden of SZ-MDD.

Keywords: antidepressant; depression; meta-analysis; prevalence; psychiatry; schizophrenia; treatment.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flow chart.
Fig. 2.
Fig. 2.
Pooled prevalence of major depressive disorder in stabilized outpatients with schizophrenia in observational studies.
Fig. 3.
Fig. 3.
Funnel plot.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fond G, Lancon C, Auquier P, Boyer L. Prévalence de la dépression majeure en France en population générale et en populations spécifiques de 2000 à 2018 : une revue systématique de la littérature. Presse Médicale. 2019;48(4):365–375. - PubMed
    1. Johnson DA. Studies of depressive symptoms in schizophrenia. Br J Psychiatry. 1981;139:89–101. - PubMed
    1. Andrianarisoa M, Boyer L, Godin O, et al. ; FACE-SCZ Group . Childhood trauma, depression and negative symptoms are independently associated with impaired quality of life in schizophrenia. Results from the national FACE-SZ cohort. Schizophr Res. 2017;185:173–181. - PubMed
    1. Godin O, Leboyer M, Schürhoff F, et al. ; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group . Predictors of rapid high weight gain in schizophrenia: longitudinal analysis of the French FACE-SZ cohort. J Psychiatr Res. 2017;94:62–69. - PubMed
    1. McGinty J, Upthegrove R. Depressive symptoms during first episode psychosis and functional outcome: a systematic review and meta-analysis. Schizophr Res. 2020;218:17–27. doi: 10.1016/j.schres.2019.12.011. - DOI - PubMed

Publication types